Sarah Gordon-Wild
Direktor/Vorstandsmitglied bei Leweston School
Vermögen: 372 497 $ am 30.04.2024
Aktive Positionen von Sarah Gordon-Wild
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Hy. Duke & Son Ltd.
Hy. Duke & Son Ltd. Specialty StoresRetail Trade Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017. | Corporate Officer/Principal | - | - |
Direktor/Vorstandsmitglied | - | - | |
Leweston School | Direktor/Vorstandsmitglied | - | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Direktor/Vorstandsmitglied | - | - |
Larkham Ltd. | Direktor/Vorstandsmitglied | - | - |
Sgw Research Ltd. | Direktor/Vorstandsmitglied | - | - |
The Bridport Literary Festival Ltd. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Sarah Gordon-Wild
Ehemalige bekannte Positionen von Sarah Gordon-Wild
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
OXFORD NANOPORE TECHNOLOGIES PLC | Direktor/Vorstandsmitglied | 01.01.2015 | 19.12.2023 |
REDX PHARMA PLC | Direktor/Vorstandsmitglied | 01.07.2020 | 30.09.2023 |
Independent Dir/Board Member | 01.07.2020 | 30.09.2023 | |
Lone Pine Capital (UK) Ltd.
Lone Pine Capital (UK) Ltd. Investment ManagersFinance Lone Pine Capital UK Ltd. (Lone Pine-UK) is the Great Britain-based alternative investment subsidiary of Lone Pine Capital LLC in the US. Headquartered in London, Lone Pine-UK was founded in 2002 and provides investment management services to pooled investment vehicles as well as pension and profit-sharing plans. | Vorstandsvorsitzender | 01.01.1998 | 01.01.2003 |
Ausbildung von Sarah Gordon-Wild
Imperial College London | Graduate Degree |
University of Aberdeen | Undergraduate Degree |
Statistik
International
Vereinigtes Königreich | 12 |
Operativ
Director/Board Member | 8 |
Corporate Officer/Principal | 1 |
Independent Dir/Board Member | 1 |
Sektoral
Consumer Services | 3 |
Health Technology | 3 |
Electronic Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
OXFORD NANOPORE TECHNOLOGIES PLC | Electronic Technology |
REDX PHARMA PLC | Health Technology |
Private Unternehmen | 7 |
---|---|
Lone Pine Capital (UK) Ltd.
Lone Pine Capital (UK) Ltd. Investment ManagersFinance Lone Pine Capital UK Ltd. (Lone Pine-UK) is the Great Britain-based alternative investment subsidiary of Lone Pine Capital LLC in the US. Headquartered in London, Lone Pine-UK was founded in 2002 and provides investment management services to pooled investment vehicles as well as pension and profit-sharing plans. | Finance |
Hy. Duke & Son Ltd.
Hy. Duke & Son Ltd. Specialty StoresRetail Trade Hy. The private company is based in Dorchester, UK, and their fine art salerooms are centrally located in the county town, close to the main Dorchester South railway station. Duke & Son Ltd. is a British company that deals with militaria and sporting goods, as well as silver and objects of vertu. The company also provides valuations for inheritance tax assessment. The company was founded in 1999, and Lee Young has been the CEO of the company since 2017. | Retail Trade |
Leweston School | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Larkham Ltd. | |
Sgw Research Ltd. | |
The Bridport Literary Festival Ltd. |
- Börse
- Insiders
- Sarah Gordon-Wild
- Erfahrung